Effective Monday, March 25, 2019, Syphilis Antibody Screen IgG [LAB3076] will change to Syphilis Total Antibody Screen [LAB1230501]. This test is also included in the Prenatal Screen (OB Panel) [LAB1230094].
Spectrum Health has been informed by Roche Diagnostics that the proprietary reagents used to calibrate our instruments and determine control values for ferritin blood level have been updated to reflect deviation of results leading to low result bias. This may have led to patient results being up to 20% lower than actual ferritin level.
Effective immediately, the OB Magnesium (Mg) reference range has been updated from 1.6 to 2.5 mg/dL to 4.8 to 8.0 mg/dL, to reflect the correct therapeutic range for patients receiving magnesium sulfate therapy. The non-OB magnesium reference range is unchanged.
Please direct questions and inquiries to Dr. Jennifer Stumph via the Contact Us link above.
OB Magnesium, Blood Level – Epic code #LAB3400, Interface code #11703, CPT code #83735
Effective immediately, Oxidative Burst by Flow Cytometry (#LAB2111414) will no longer require submission of the biological mother’s sample. An adult control specimen will still be required along with the patient’s specimen. For more information on specimen collection, please visit the Laboratory Catalog.
Questions may be directed to the Flow Cytometry Laboratory using the “Contact Us” link above.
High sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria (PNH) is a test done on patient’s peripheral blood to screen for the presence or absence of PNH clones and/or to follow PNH clonal populations. The lower limit of detection of a PNH clone for the Spectrum Health laboratory has been validated as 0.01% (1:10,000) for red cells, 0.01% (1:10,000) for granulocytes and 0.1% for monocytes (1:1000).
The results from PNH flow cytometry testing can guide the clinical team in classifying a patient’s disease appropriately, analyzing the risk of disease progression, and choosing appropriate testing to monitor response to treatment. Therefore, the PNH flow cytometry test result will now include a pathologist’s interpretation based on the new recommendations given in Updated ICCS/ESCCA Consensus Guidelines for the Clinical Utility of Testing for GPI-Anchor Deficient Clones in Paroxysmal Nocturnal Hemoglobinuria (PNH) and other Bone Marrow Disorders (Accepted article by Dezern and Borowitz, doi: 10.1002/cyto.b.21608).
The Spectrum Health Flow Cytometry Laboratory is pleased to announce that it has attained status as a Children’s Oncology Group (COG) approved laboratory for minimal residual disease (MRD) testing for patients with B lymphoblastic leukemia (B-ALL). This is a reflection of the expertise and dedication of the entire flow cytometry team to accomplish this 3-year project. It also highlights the strong support and collaboration between the laboratory and pediatric hematology oncology team.